Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study

Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study

Sábháilte in:

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Matteo Santoni, Zin Myint, Thomas Büttner, Hideki Takeshita, Y. Okada, Elaine T. Lam, Danielle Gilbert, Zsófia Kürönya, Deniz Tural, Renate Pichler, Enrique Grande, Simon J. Crabb, ROBERT COLEMAN KEMP, Francesco Massari, Sarah Scagliarini, Roberto Iacovelli, Nuno Vau, Umberto Basso, Marco Maruzzo, Javier Molina‐Cerrillo, Luca Galli, Aristotelis Bamias, Ugo De Giorgi, Paolo Andrea Zucali, Mimma Rizzo, Emmanuel Seront, Lazar Popović, Orazio Caffo, Sebastiano Buti, Ravindran Kanesvaran, Jindřich Kopecký, Jakub Kucharz, Annalisa Zeppellini, Ondřej Fiala, Johannes Landmesser, Jawaher Ansari, Patrizia Giannatempo, Alessandro Rizzo, Ignacio Ortego Zabalza, Fernando Sabino Marques Monteiro, Nicola Battelli, Fabio Calabrò, Camillo Porta
Formáid:	Artigo
Teanga:	Béarla
Foilsithe / Cruthaithe:	2023
Rochtain ar líne:	https://doi.org/10.1007/s00262-023-03469-5
Clibeanna:	Cuir clib leis Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!

Míreanna comhchosúla

Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)
de réir: Matteo Santoni, et al.
Foilsithe / Cruthaithe: (2023)

Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de‐differentiation (ARON‐1 study)
de réir: Chiara Ciccarese, et al.
Foilsithe / Cruthaithe: (2024)

Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study
de réir: Francesco Massari, et al.
Foilsithe / Cruthaithe: (2024)

Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study
de réir: Ondřej Fiala, et al.
Foilsithe / Cruthaithe: (2023)

Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study
de réir: Camillo Porta, et al.
Foilsithe / Cruthaithe: (2025)

Real‐Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The <scp>ARON</scp>‐2 Retrospective Experience
de réir: Mimma Rizzo, et al.
Foilsithe / Cruthaithe: (2025)

Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study
de réir: Mimma Rizzo, et al.
Foilsithe / Cruthaithe: (2024)

Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study
de réir: Ondřej Fiala, et al.
Foilsithe / Cruthaithe: (2024)

Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 Study
de réir: Matteo Santoni, et al.
Foilsithe / Cruthaithe: (2024)

Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2EV study
de réir: Ondřej Fiala, et al.
Foilsithe / Cruthaithe: (2025)

Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study)
de réir: Ondřej Fiala, et al.
Foilsithe / Cruthaithe: (2024)

Aron, Raymond. Memórias
de réir: Catani, Afrânio Mendes
Foilsithe / Cruthaithe: (1987)

Aron, Raymond. Memórias
de réir: Afrânio Mendes Catani
Foilsithe / Cruthaithe: (1987)

First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study
de réir: Giandomenico Roviello, et al.
Foilsithe / Cruthaithe: (2025)

Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations
de réir: Camillo Porta, et al.
Foilsithe / Cruthaithe: (2023)

Biological Therapeutic Advances for the Treatment of Advanced Urothelial Cancers
de réir: Rizzo, Mimma, et al.
Foilsithe / Cruthaithe: (2021)

Dr. Arons—Information Wanted
Foilsithe / Cruthaithe: (1905)

Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab
de réir: Lorena Incorvaia, et al.
Foilsithe / Cruthaithe: (2025)

Reply to Aron P. Kater et al.
de réir: Moia, Riccardo, et al.
Foilsithe / Cruthaithe: (2020)

Beyond Raymond Aron The First Reception of Dilthey in France
de réir: MACHADO, Hallhane
Foilsithe / Cruthaithe: (2024)

Ineligibility
de réir: Wilson, J. M. M.
Foilsithe / Cruthaithe: (1967)

Aberrations of DNA Repair Pathways in Prostate Cancer: Future Implications for Clinical Practice?
de réir: Caffo, Orazio, et al.
Foilsithe / Cruthaithe: (2018)

Metastatic castration-resistant prostate cancer in very elderly patients: challenges and solutions
de réir: Caffo, Orazio, et al.
Foilsithe / Cruthaithe: (2016)

RAYMOND ARON: ENGAJAMENTO E POLÍTICA NO CONTEXTO DA SOCIEDADE INDUSTRIAL
de réir: Dias Junior, Antonio Carlos
Foilsithe / Cruthaithe: (2018)

Aron Gurwitsch, intérprete de Kurt Goldstein: a intencionalidade categorial
de réir: Hernani Pereira dos Santos, et al.
Foilsithe / Cruthaithe: (2017)

A Autoconsciência na Teoria de Aron Gurwitsch: Posição e Crítica
de réir: Pedro Henrique Santos Decanini Marangoni, et al.
Foilsithe / Cruthaithe: (2020)

Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence
de réir: Rizzo, Mimma, et al.
Foilsithe / Cruthaithe: (2017)

Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence
de réir: Mimma Rizzo, et al.
Foilsithe / Cruthaithe: (2017)

Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations
de réir: Lorena Incorvaia, et al.
Foilsithe / Cruthaithe: (2024)

Pathological complete response induced by first-line chemotherapy with single agent docetaxel in a patient with advanced non small cell lung cancer
de réir: Riccardi, Ferdinando, et al.
Foilsithe / Cruthaithe: (2010)

Removal of ineligible outcome cases reduces confounding
de réir: Walker, Alexander M, et al.
Foilsithe / Cruthaithe: (2018)

Defining optimal therapy for the thrombolysis‐ineligible patient
de réir: Cohen, Marc
Foilsithe / Cruthaithe: (2007)

Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
de réir: Lotfi Benboubker, et al.
Foilsithe / Cruthaithe: (2014)

Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib
de réir: Iacovelli, Roberto, et al.
Foilsithe / Cruthaithe: (2014)

Beyond abstraction: applying the brakes to runaway patent ineligibility
de réir: Burk, Dan L.
Foilsithe / Cruthaithe: (2016)

Single nucleotide polymorphisms in angiogenesis-related genes and outcomes from antiangiogenic therapies in renal cell carcinoma: really a step towards personalized oncology, or not at all?
de réir: Porta, Camillo, et al.
Foilsithe / Cruthaithe: (2019)

Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?
de réir: Santoni, Matteo, et al.
Foilsithe / Cruthaithe: (2021)

Sequencing of PD-1/L1 inhibitors and Carboplatin-based Chemotherapy for Cisplatin-Ineligible Metastatic Urothelial Carcinoma
de réir: Wei, Xiao X., et al.
Foilsithe / Cruthaithe: (2020)

Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma
de réir: Xiao X. Wei, et al.
Foilsithe / Cruthaithe: (2020)

Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma
de réir: Iacovelli, Roberto, et al.
Foilsithe / Cruthaithe: (2015)